Savara Inc (SVRA) - Total Liabilities
Based on the latest financial reports, Savara Inc (SVRA) has total liabilities worth $50.30 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Savara Inc (SVRA) equity growth momentum to track the company's year-over-year net asset growth rate.
Savara Inc - Total Liabilities Trend (2000–2025)
This chart illustrates how Savara Inc's total liabilities have evolved over time, based on quarterly financial data.
Savara Inc Competitors by Total Liabilities
The table below lists competitors of Savara Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Dorian LPG Ltd
NYSE:LPG
|
USA | $713.63 Million |
|
Wuxi Xinhongye Wire & Cable Co. Ltd. A
SHE:301310
|
China | CN¥3.36 Billion |
|
FAWER Automotive Parts Ltd Co
SHE:000030
|
China | CN¥9.40 Billion |
|
Electro Optic Systems Holdings Ltd
AU:EOS
|
Australia | AU$136.69 Million |
|
Hyundai Wia
KO:011210
|
Korea | ₩2.96 Trillion |
|
Safety Insurance Group Inc
NASDAQ:SAFT
|
USA | $1.58 Billion |
|
McEwen Mining Inc.
TO:MUX
|
Canada | CA$319.81 Million |
|
Wuxi Online Offline Communication Information Technology Co. Ltd.
SHE:300959
|
China | CN¥184.80 Million |
Liability Composition Analysis (2000–2025)
This chart breaks down Savara Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Savara Inc (SVRA) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 11.85 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.25 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.20 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Savara Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Savara Inc (2000–2025)
The table below shows the annual total liabilities of Savara Inc from 2000 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $50.30 Million | +21.42% |
| 2024-12-31 | $41.43 Million | +11.39% |
| 2023-12-31 | $37.19 Million | +16.23% |
| 2022-12-31 | $32.00 Million | -0.31% |
| 2021-12-31 | $32.10 Million | -3.78% |
| 2020-12-31 | $33.36 Million | -3.31% |
| 2019-12-31 | $34.51 Million | -77.34% |
| 2018-12-31 | $152.29 Million | +277.71% |
| 2017-12-31 | $40.32 Million | -37.79% |
| 2016-12-31 | $64.81 Million | +113.69% |
| 2015-12-31 | $30.33 Million | +156.11% |
| 2014-12-31 | $11.84 Million | +59.12% |
| 2013-12-31 | $7.44 Million | +43.69% |
| 2012-12-31 | $5.18 Million | +2.02% |
| 2011-12-31 | $5.08 Million | +181.82% |
| 2010-12-31 | $1.80 Million | -23.46% |
| 2009-12-31 | $2.35 Million | -50.07% |
| 2008-12-31 | $4.71 Million | +34.41% |
| 2007-12-31 | $3.51 Million | -89.32% |
| 2006-12-31 | $32.84 Million | +4.42% |
| 2005-12-31 | $31.45 Million | +2481.29% |
| 2004-12-31 | $1.22 Million | +647.29% |
| 2003-12-31 | $163.04K | -83.41% |
| 2002-12-31 | $983.08K | +7.26% |
| 2001-12-31 | $916.49K | +241.25% |
| 2000-12-31 | $268.57K | -- |
About Savara Inc
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Langhorne,… Read more